Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/22/2022 8-K Resignation/termination of a director
Docs: "FIRST:",
"THIRD AMENDED AND RESTATED BYLAWS OF BIODELIVERY SCIENCES INTERNATIONAL, INC."
02/14/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...
Docs: "EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER",
"AMENDMENT NO. 1TOSECOND AMENDED AND RESTATEDBYLAWS OFBIODELIVERY SCIENCES INTERNATIONAL, INC.",
"Collegium to Acquire BioDelivery Sciences in an All-Cash Deal"
01/20/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance"
11/03/2021 8-K Quarterly results
Docs: "BioDelivery Sciences Reports Solid Third Quarter 2021 Results"
10/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/27/2021 8-K Quarterly results
09/21/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
Docs: "BioDelivery Sciences Reports Second Quarter 2021 Results"
07/30/2021 8-K Submission of Matters to a Vote of Security Holders
07/27/2021 8-K Other Events
07/07/2021 8-K Regulation FD Disclosure
05/06/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/05/2020 8-K Quarterly results
Docs: "BioDelivery Sciences Reports Strong Q3 2020 Results",
"BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO",
"BioDelivery Sciences Announces $25 Million Share Repurchase Program"
10/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/05/2020 8-K Quarterly results
07/24/2020 8-K Quarterly results
05/22/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
05/12/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
01/13/2020 8-K Results of Operations and Financial Condition
Docs: "BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic 2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million"
12/20/2019 8-K Quarterly results
11/25/2019 8-K Financial Statements and Exhibits
Docs: "BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors"
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "FORM 8-K",
"BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations"
07/25/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Certificate of Incorporation of BioDelivery Sciences International, Inc",
"Certificate of Amendment to the Certificate of Incorporation of BioDelivery Sciences International, Inc"
05/28/2019 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15 of the Securities Exchange Act of 1934 Date of Report : May 28, 2019 BioDelivery Sciences International, Inc. Delaware 001-31361 35-2089858 File Number) Identification No.) 4131 ParkLake Ave., Suite #225 Raleigh, NC 27612 Registrant's telephone number, including area code: 919-582-9050 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications ...",
"BioDelivery Sciences Strengthens Financial Position with Debt Refinancing"
05/06/2019 8-K Quarterly results
Docs: "FORM 8-K",
"BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA ® Full-Year Expectations"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy